Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries

Keyphrases

• Health Registries 100%
• Matched Cohort Study 100%
• Osteoporosis 100%
• Zoledronic Acid 100%
• Cardiovascular Mortality 27%
• Oral Bisphosphonates 27%
• Heart Failure 18%
• Propensity Score Matching 18%
• Matched Cohort 18%
• Population Control 18%
• Denmark 9%
• Event Rate 9%
• High Risk 9%
• Sensitivity Analysis 9%
• All-cause Mortality 9%
• Sweden 9%
• Atrial Fibrillation 9%
• Substantial Change 9%
• Cardiovascular Risk 9%
• Cardiovascular Outcomes 9%
• National Register 9%
• Arrhythmia 9%
• Drug Effects 9%
• Baseline Risk 9%
• Heart Failure Risk 9%
• Exposure Time 9%
• Failure Fracture 9%
• Severe Osteoporosis 9%
• Acid Treatment 9%
• Safety Study 9%

Medicine and Dentistry

• Cohort Analysis 100%
• Cardiovascular System 100%
• Osteoporosis 100%
• Zoledronic Acid 100%
• Cardiovascular Mortality 27%
• Bisphosphonate 27%
• Congestive Heart Failure 27%
• Heart Death 9%
• All Cause Mortality 9%
• Atrial Fibrillation 9%
• Cardiovascular Risk 9%
• Propensity Score Matching 9%
• Cardiac Dysrhythmia 9%
• Drug Effect 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Cohort Study 100%
• Zoledronic Acid 100%
• Bisphosphonic Acid Derivative 27%
• Cardiovascular Mortality 27%
• Congestive Heart Failure 27%
• Heart Death 9%
• All Cause Mortality 9%
• Heart Arrhythmia 9%
• Cardiovascular Risk 9%
• Atrial Fibrillation 9%